Investment Rating - The report maintains a "Buy" rating for the company, 百济神州 (6160 HK) [2][11]. Core Insights - The company demonstrated strong product sales in Q4 2025, with revenue reaching USD 1.476 billion, a year-on-year increase of 32%. The sales of the drug, Zejula, amounted to USD 1.1 billion, with a significant market share in the US [6]. - The company is increasing its R&D investments in 2026, focusing on pipeline development and prioritizing management, which is expected to yield multiple catalysts [2][6]. - The revenue guidance for 2026 is set between RMB 62-64 billion, with a projected non-GAAP net profit of RMB 14-15 billion [6]. Financial Performance - The company’s revenue for 2026 is forecasted at RMB 6,317 million, a decrease of 3% from previous estimates. The gross profit is expected to be RMB 5,564 million, down by 1% [5]. - The gross profit margin is projected to be 88.0%, an increase of 0.9 percentage points compared to previous estimates [5]. - The GAAP net profit for 2026 is estimated at RMB 750 million, reflecting a 15% decrease from prior forecasts [5]. Stock Performance - The stock price closed at HKD 194.40, with a target price adjusted to HKD 229.20, indicating a potential upside of 17.9% [1][11]. - The stock has shown a year-to-date change of 8.42% [4]. Pipeline Development - The company is focusing on four core strategic areas for pipeline development: chronic lymphocytic leukemia (CLL), other hematological malignancies, solid tumors, and inflammation/immune diseases [6]. - Key upcoming milestones include the potential approval of Sotigalimab in the US and Europe, and the initiation of several clinical trials for new therapies [6].
百济神州：4Q25产品销售强势、利润端略有波动，2026研发多点开花；维持买入-20260302